PTPN1 and cancer: Moreover, AbbVie/Calico Life Science declaimed that they discovered some specific inhibitors targeting TCPTP and/or PTP1B, which may be useful for the treatment of cancer or metabolic diseases, and some of them have already been in clinical trials [34].